J
Jef J. Emeis
Researcher at VU University Amsterdam
Publications - 50
Citations - 5546
Jef J. Emeis is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Fibrinolysis & Cholesterol. The author has an hindex of 25, co-authored 50 publications receiving 5373 citations. Previous affiliations of Jef J. Emeis include University of Münster.
Papers
More filters
Journal ArticleDOI
C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction A Potential Role for Cytokines Originating From Adipose Tissue?
TL;DR: The data suggest that adipose tissue is an important determinant of a low level, chronic inflammatory state as reflected by levels of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein, and that infection with H pylori, C pneumoniae, and cytomegalovirus is not.
Journal ArticleDOI
Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death
Coen D.A. Stehouwer,M. A. Gall,Jos W. R. Twisk,Elisabeth Knudsen,Jef J. Emeis,Hans-Henrik Parving +5 more
TL;DR: In type 2 diabetes, increased urinary albumin excretion, endothelial dysfunction, and chronic inflammation are interrelated processes that develop in parallel, progress with time, and are strongly and independently associated with risk of death.
Journal ArticleDOI
von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study.
A. Jager,Victor W.M. van Hinsbergh,Piet J. Kostense,Jef J. Emeis,John S Yudkin,Giel Nijpels,Jacqueline M. Dekker,R. J. Heine,Lex M. Bouter,Coen D.A. Stehouwer +9 more
TL;DR: Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects, favoring the hypothesis that vWf and CRP predict mortality through different pathways.
Journal ArticleDOI
Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin
Robert Kleemann,Hans M.G. Princen,Jef J. Emeis,J. Wouter Jukema,Ruud D. Fontijn,Anton J.G. Horrevoets,Teake Kooistra,Louis M. Havekes +7 more
TL;DR: Rosuvastatin reduces atherosclerosis beyond and independent of the reduction achieved by cholesterol lowering alone, and this additional beneficial effect of rosuvastatin may be explained, at least partly, by its anti-inflammatory activity.
Journal ArticleDOI
Simvastatin Improves Disturbed Endothelial Barrier Function
Geerten P. van Nieuw Amerongen,Mario A. Vermeer,Pascale Nègre-Aminou,Jan Lankelma,Jef J. Emeis,Victor W.M. van Hinsbergh +5 more
TL;DR: The data show that simvastatin, in a relatively high concentration, improves disturbed endothelial barrier function both in vitro and in vivo, and support the beneficial effects of simVastatin in acute coronary events by mechanisms other than its lipid-lowering effect.